AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) will be releasing its earnings data after the market closes on Tuesday, November 6th. Analysts expect AEterna Zentaris to post earnings of ($0.25) per share for the quarter.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.16. AEterna Zentaris had a net margin of 6.76% and a return on equity of 20.71%. The company had revenue of $0.17 million during the quarter. On average, analysts expect AEterna Zentaris to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AEZS opened at $2.23 on Monday. AEterna Zentaris has a twelve month low of $1.12 and a twelve month high of $3.25. The firm has a market cap of $36.66 million, a PE ratio of -1.65 and a beta of 0.75.
Several brokerages recently issued reports on AEZS. Zacks Investment Research raised shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research note on Tuesday, October 9th. ValuEngine lowered shares of AEterna Zentaris from a “sell” rating to a “strong sell” rating in a research note on Monday, September 17th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $2.92.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.